NeoGenomics (NEO +5.3%) launches three liquid biopsy tests for advanced non-small cell lung cancer, all solid tumor types (pan-cancer), and certain breast cancer cases.
These new tests provide a peripheral blood option for detection of therapeutic targets and prognostic markers, and the three new assays have a turnaround time of seven days or less.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.